SCHEMBL21049906

SCHEMBL21049906

O=C(O)NCCc1cccc(-c2cccc(CO)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.53
ACMSD Q8TDX5 2/20 0.51
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
PRKCI P41743 1/20 0.47
PLAAT3 P53816 1/20 0.46
PLAAT5 Q96KN8 1/20 0.46
PLAAT2 Q9NWW9 1/20 0.46
PLAAT4 Q9UL19 1/20 0.46
MTNR1A P48039 3/20 0.46
MTNR1B P49286 3/20 0.46
ALDH1A1 P00352 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
PTGER4 P35408 2/20 0.45
CNR2 P34972 1/20 0.44
AOC3 Q16853 1/20 0.44
CA12 O43570 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2635816 0.92 NPC1 (0.53) NPC1RAB9APLAAT3PLAAT5PLAAT2
SCHEMBL5374261 0.84 PLAAT3 (0.49) ACMSDPLAAT3PLAAT5PLAAT2PLAAT4
SCHEMBL16396868 0.83 AOC3 (0.58) ACMSDPRKCIPTGER4CNR2AOC3
SCHEMBL3345753 0.82 FAAH (0.53) AKR1C3NPC1RAB9AAOC3
SCHEMBL3948564 0.81 PLAAT3 (0.50) AKR1C3ACMSDNPC1RAB9APLAAT3
SCHEMBL3340166 0.81 AOC3 (0.51) NPC1RAB9APLAAT3PLAAT5PLAAT2
SCHEMBL15111915 0.80 RAB9A (0.57) NPC1RAB9A
SCHEMBL21089804 0.79 NQO2 (0.49) AKR1C3MTNR1AMTNR1BCA2
SCHEMBL2749289 0.78 SPR (0.63) NPC1RAB9APLAAT3PLAAT5PLAAT2
SCHEMBL11895626 0.78 NPC1 (0.65) AKR1C3NPC1RAB9AMTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577383-B2 Macrocyclic inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-03 US disclosed
US-20190177340-A1 MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2019-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177340-A1 MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 AKR1C3 873/4885ACMSD 2398/4885NPC1 1157/4885
US-10577383-B2 Macrocyclic inhibitors of myeloperoxidase EPX, MPO, SERPINB1 AKR1C3 873/4885ACMSD 2398/4885NPC1 1157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.